Centrex Announces Patent Publication
Centrex, Inc., Tulsa
Ron Wheet, 843-971-4848 www.centrexcorporation.com
Centrex, Inc. (OTCBB:CNEX) today announced the issuance by the U.S. Patent Office of the patent that covers the single molecule nucleic acid detection technology (SMD) which forms the core of Centrex's planned multi-channel biopathogen detection system. The patent for this unique platform technology is owned by Los Alamos National Laboratory (LANL) and the University of California.
Centrex owns the exclusive worldwide license to develop, manufacture, and market a system for detecting microbial contamination utilizing the SMD technology. The SMD technology, in combination with an easy-to-operate lab card device and integrated reader, is expected to be responsive to the need for rapid, user friendly and cost effective solutions for point-of-use analyses of a variety of bacterial and viral organisms.
Centrex's SMD technology offers important advantages over existing DNA and RNA detection methods as well as culture-based test methods. SMD technology eliminates the need for amplification of the target DNA or RNA by recognizing the unique DNA or RNA fingerprint of the target organism directly. This reduces the possibility of false positive and negative test results -- common concerns frequently identified with other test procedures.
Centrex is focusing commercial efforts on the development of a product that uses SMD as part of a simultaneous, multi-channel detection system that is compact, fully automated and capable of monitoring the presence of biological agents in air, food and water. Potential applications for the SMD technology include bioterrorism and Homeland Security, monitoring of air quality, food and water processing, blood supply screening, and general DNA/RNA testing.
For more information call Ron Wheet at 843-971-4848 or visit the Centrex website at www.centrexcorporation.com.
This press release contains certain forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in the Company's SEC filings.